Drug profile

The FDA adverse-event record for Desoxycorticosterone Pivalate (Docp)

51 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Desoxycorticosterone Pivalate (Docp). See the species affected, top reactions, and outcomes below.

51
adverse-event reports
5.9%
death-coded share
Dog
most-reported species
21
Immediate pain upon injection - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
51
Total Reports
3
Deaths Reported
5.9%
Death Rate

Active Ingredients

Desoxycorticosterone Pivalate (Docp)

Administration Routes

UnknownIntramuscularSubcutaneous

Species Affected

Dog 51

Most Affected Breeds

Retriever - Labrador 7
Poodle - Standard 6
Retriever - Golden 5
Boxer (German Boxer) 3
Shepherd Dog - German 2
Dog (unknown) 2
Poodle - Miniature 2
Pointing Dog - German Short-haired 2
Dog (other) 2
Crossbred Canine/dog 2

Most Reported Reactions

Immediate pain upon injection 21
Vocalisation 11
Lethargy (see also Central nervous system depression in 'Neurological') 8
Diarrhoea 7
Polydipsia 7
Polyuria 7
Vomiting 5
High sodium-potassium ratio (Na:K ratio) 4
Dehydration 4
Anorexia 4
Weakness 4
Inappropriate urination 3

Outcome Breakdown

Recovered/Normal
31 (60.8%)
Outcome Unknown
13 (25.5%)
Ongoing
4 (7.8%)
Died
3 (5.9%)

Desoxycorticosterone Pivalate (Docp) Adverse Event Insights

51 reports name Desoxycorticosterone Pivalate (Docp); 3 recorded a death outcome (5.9% of reported events, not a population-level mortality rate). Active ingredient: Desoxycorticosterone Pivalate (Docp). Administration routes: Unknown, Intramuscular, Subcutaneous.

By species: Dog (51 reports). By breed: Retriever - Labrador (7), Poodle - Standard (6), Retriever - Golden (5).

Leading clinical signs: Immediate pain upon injection (21), Vocalisation (11), Lethargy (see also Central nervous system depression in 'Neurological') (8), Diarrhoea (7). Outcome, 51 coded reports: Recovered/Normal leads at 60.8%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.